Oligometastatic Disease Management: Finding the Sweet Spot
Open Access
- 22 December 2020
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 617793
Abstract
Hematogenous dissemination represents a common manifestation of squamous cell carcinoma of the head and neck, and the recommended therapeutic options usually consist of systemically administered drugs with palliative intent. However, mounting evidence suggests that patients with few and slowly progressive distant lesions of small size may benefit from various local ablation techniques, which have already been established as standard-of-care modalities for example in colorectal and renal cell carcinomas and in sarcomas. In principle, serving as radical approaches to eradicate cancer, these interventions can be curative. Their impact on local control and overall survival has been shown in numerous retrospective and prospective studies. The term oligometastatic refers to the number of distant lesions which should generally not surpass five in total, ideally in one organ. Currently, surgical resection remains the method of choice supported by the majority of published data. More recently, stereotactic (ablative) body radiotherapy (SABR/SBRT) has emerged as a viable alternative. In cases technically amenable to such local interventions, several other clinical variables need to be taken into account also, including patient-related factors (general health status, patient preferences, socioeconomic background) and disease-related factors (primary tumor site, growth kinetics, synchronous or metachronous metastases). In head and neck cancer, patients presenting with late development of slowly progressive oligometastatic lesions in the lungs secondary to human papillomavirus (HPV)-positive oropharyngeal cancer are the ideal candidates for metastasectomy or other local therapies. However, literature data are still limited to say whether there are other subgroups benefiting from this approach. One of the plausible explanations is that radiological follow-up after primary curative therapy is usually not recommended because its impact on survival has not been unequivocal, which is also due to the rarity of oligometastatic manifestations in this disease. At the same time, aggressive treatment of synchronous metastases early in the disease course should be weighed against the risk of futile interventions in a disease with already multimetastatic microscopic dissemination. Therefore, attentive treatment sequencing, meticulous appraisal of cancer extension, refinement of post-treatment surveillance, and understanding of tumor biology and kinetics are crucial in the management of oligometastases.Keywords
This publication has 64 references indexed in Scilit:
- Distant metastases from head and neck squamous cell carcinoma. Part II. DiagnosisOral Oncology, 2012
- Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspectsOral Oncology, 2012
- 18FDG-PET/CT for detecting distant metastases and second primary cancers in patients with head and neck cancer. A meta-analysisOral Oncology, 2011
- Squamous cell cancer of the head and neck with distant metastasis at presentationHead & Neck, 2010
- Positron Emission Tomography With [18F]Fluorodeoxyglucose Improves Staging and Patient Management in Patients With Head and Neck Squamous Cell Carcinoma: A Multicenter Prospective StudyJournal of Clinical Oncology, 2010
- Distant metastases in head and neck carcinoma: Identification of prognostic groups with MR imagingEuropean Journal of Radiology, 2006
- Incidence and Sites of Distant Metastases from Head and Neck CancerORL, 2001
- Stereotactic High Dose Fraction Radiation Therapy of Extracranial Tumors Using An Accelerator: Clinical experience of the first thirty-one patientsActa Oncologica, 1995
- Stereotactic Radiotherapy of Malignancies in the Abdomen: Methodological aspectsActa Oncologica, 1994
- The surgical treatment of pulmonary metastasesCancer Treatment Reviews, 1978